

Epizyme, Inc.  
 Form 3  
 October 01, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |                                      |  |  |
|---|---------|--------------------------------------|--|--|
| 1. Name and Address of Reporting Person * |         | 2. Date of Event Requiring Statement | 3. Issuer Name and Ticker or Trading Symbol                            |  |
| Â Garbacz Stephen                         |         | (Month/Day/Year)                     | Epizyme, Inc. [EPZM]   |  |
| (Last)                                    | (First) | (Middle)                             | 4. Relationship of Reporting Person(s) to Issuer                       | 5. If Amendment, Date Original Filed(Month/Day/Year) |
|   |         | 10/01/2014                           |  |  |
| C/O EPIZYME, INC.,Â 400 TECHNOLOGY SQUARE |         |                                      | (Check all applicable)   |  |
| (Street)                                  |         |                                      | <input type="checkbox"/> Director                                      | <input type="checkbox"/> 10% Owner                   |
|   |         |                                      | <input checked="" type="checkbox"/> Officer                            | <input type="checkbox"/> Other                       |
|   |         |                                      | (give title below)   | (specify below)                                      |
| CAMBRIDGE,Â MAÂ 02139                     |         |                                      | Principal Accounting Officer   |  |
| (City)                                    | (State) | (Zip)                                | 6. Individual or Joint/Group Filing(Check Applicable Line)             |  |
|   |         |                                      | <input checked="" type="checkbox"/> Form filed by One Reporting Person |  |
|   |         |                                      | <input type="checkbox"/> Form filed by More than One Reporting Person  |  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security (Instr. 4)            | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|---|--|---|
| Common Stock, par value \$0.0001 per share | 13,073  | D  | Â   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|---|--|--|---|
|--|--|---|--|--|---|

Edgar Filing: Epizyme, Inc. - Form 3

|                             | Date Exercisable | Expiration Date |              | Amount or Number of Shares |          | or Indirect (I) (Instr. 5) |   |
|-----------------------------|------------------|-----------------|--------------|----------------------------|----------|----------------------------|---|
| Stock Option (Right to Buy) | Â (1)            | 10/02/2022      | Common Stock | 23,438                     | \$ 2.19  | D                          | Â |
| Stock Option (Right to Buy) | Â (2)            | 01/24/2023      | Common Stock | 18,745                     | \$ 3.54  | D                          | Â |
| Stock Option (Right to Buy) | Â (3)            | 09/02/2023      | Common Stock | 15,000                     | \$ 28.04 | D                          | Â |
| Stock Option (Right to Buy) | Â (4)            | 01/27/2024      | Common Stock | 14,000                     | \$ 31.2  | D                          | Â |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                                |       |
|--|---------------|-----------|--------------------------------|-------|
|  | Director      | 10% Owner | Officer                        | Other |
| Garbacz Stephen<br>C/O EPIZYME, INC.<br>400 TECHNOLOGY SQUARE<br>CAMBRIDGE, MA 02139 | Â             | Â         | Â Principal Accounting Officer | Â     |

## Signatures

/s/ Stephen Garbacz 10/01/2014

\*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on October 3, 2012 with respect to 41,666 shares of Common Stock, with 25% vesting on October 3, 2013 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
- (2) This option was granted on January 25, 2013 with respect to 25,700 shares of Common Stock, with 25% vesting on January 25, 2014 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
- (3) This option was granted on September 3, 2013 with respect to 15,000 shares of Common Stock, with 25% vesting on September 3, 2014 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
- (4) This option was granted on January 28, 2014 with respect to 14,000 shares of Common Stock, with 25% vesting on January 28, 2015 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.